Last updated: Sep 9, 2026 · Built by a patient who got tired of scrolling ClinicalTrials.gov
Active interventional trials with status RECRUITING or NOT_YET_RECRUITING. A multi-phase trial (e.g. 1/2) is counted in each of its phases.
Biomarkers, stage, prior treatments — get a ranked shortlist in minutes.
Recruiting trials grouped by drug class. Trials with unclassifiable or non-therapeutic interventions are excluded from this view.
| NCT | Phase | Title | Mechanism |
|---|---|---|---|
| NCT07360119 | — | Total Pancreatectomy With Islet Autotransplantation (TPIAT) for High-Risk Patients With Pancreatic Tumors | Unknown mechanism |
| NCT03608631 | 1, 2 | iExosomes in Treating Participants With Metastatic Pancreas Cancer With KrasG12D Mutation | KRAS G12D -- siRNA delivered by mesenchymal stromal cell-derived exosomes |
| NCT06400472 | 1 | A Study of Sofe-M in Participants With Selected Advanced Solid Tumors | Unknown mechanism |
| NCT04005690 | 1 | Targeted Pathway Inhibition in Patients With Pancreatic Cancer | MEK -- MEK inhibitor (cobimetinib); PARP -- PARP inhibitors (olaparib, saruparib); PLK1 -- PLK1 inhibitor (onvansertib); WEE1 -- WEE1 inhibitor (azenosertib) |
| NCT04858334 | 2 | APOLLO: A Randomized Phase II Double-Blind Study of Olaparib Versus Placebo Following Curative Intent Therapy in Patients With Resected Pancreatic Cancer and a Pathogenic BRCA1, BRCA2 or PALB2 Mutation | PARP inhibition (Olaparib) |
| Sponsor | Recruiting trials |
|---|---|
| Fudan University | 19 |
| Tianjin Medical University Cancer Institute and Hospital | 14 |
| Ruijin Hospital | 13 |
| Zhejiang University | 12 |
| West China Hospital | 9 |
Countries/regions with the most active trial sites for pancreatic cancer. A multi-site trial is counted once per country/region.
Phase-1 trials whose listed start date falls within the last 12 months — the leading edge of the field.
| Start | NCT | Title | Mechanism |
|---|---|---|---|
| Dec 16, 2026 | NCT07608627 | 64Cu-DOTA A2 scFv-Fc2 DM With Positron Emission Tomography for the Imaging of Patients With Locally Advanced or Metastatic PSCA-Expressing Pancreatic Cancer | PSCA -- radiolabeled antibody fragment for imaging (radioconjugate) |
| Nov 1, 2026 | NCT07587827 | Study Evaluating the Safety Feasibility and Efficacy of ODI-2001 Vaccine, a Personnalized Immunotherapy in Patients With Metastatic or Locally Advanced Colon Cancer or Pancreatic Cancer | Neoantigens + CTLA-4 -- personalized DNA neoantigen vaccine combined with immune checkpoint blockade (anti-CTLA4 antibody) |
| Nov 2026 | NCT07738939 | IKS04 Regimen in Advanced Solid Tumors That Express CA242 | CA242 -- antibody-drug conjugate (ADC) |
| Sep 30, 2026 | NCT07394205 | Clinical Study of CBG131 CAR-T Cell Injection for the Treatment of CLDN18.2-Positive Advanced Gastric and Pancreatic Cancer | CLDN18.2 -- CAR-T cell therapy |
| Sep 15, 2026 | NCT07645651 | Samuraciclib for the Treatment of Patients With Resectable, Borderline Resectable, or Locally Advanced Basal Pancreatic Cancer | CDK7 -- kinase inhibitor (small molecule) |
| Sep 10, 2026 | NCT07802184 | GnP Combined With SHR-1701 and Apatinib as First-Line Treatment for Locally Advanced or Metastatic PDAC | PD-L1 + TGF-β receptor -- bispecific antibody (SHR-1701) + VEGFR2 -- tyrosine kinase inhibitor (Apatinib) |
| Sep 8, 2026 | NCT07619521 | Testing the Combination of Anti-Cancer Drugs, Selumetinib and DS-8201a, for Advanced Pancreatic Ductal Adenocarcinoma | MEK1/2 + HER2 -- MEK inhibitor + antibody-drug conjugate (ADC) |
| Sep 2026 | NCT07698613 | EGFR Targeted Photoimmunotherapy With ASP-1929 for Locally Advanced Pancreatic Cancer | EGFR -- antibody-photoabsorber conjugate (photoimmunotherapy) |
You've seen the pancreatic cancer landscape. Now find the trials that fit your case.
Enter biomarkers, stage, and prior treatments — get ranked matches with eligibility breakdown in minutes.
Find My Matches →Source: ClinicalTrials.gov, synced daily. Aggregated by ClinTrialFinder.